Federal regulators have granted a special designation to a Portland company’s digital therapeutics program that is under development to fast-track the product’s rollout.
MedRhythms is building a direct simulation that uses sensors, music and software to lessen walking impairments brought on by stroke.
The company on Monday had its program designated a “breakthrough device” by the U.S. Food and Drug Administration. The designation means MedRhythms can speed up development, assessment and review of its product and interact with FDA experts to address topics as they arise during pre-market review and get prioritized submission review.
“I am pleased that our commitment to generating rigorous clinical evidence has allowed us to demonstrate our product’s merit and to be recognized as a breakthrough device,” said Danielle Briggeman, MedRhythms’ clinical and regulatory affairs manager.
Stroke is a leading cause of disability, and more than half of stroke survivors, 3.5 million people, have long-term walking defects, the company said.
Comments are not available on this story. Read more about why we allow commenting on some stories and not on others.
We believe it's important to offer commenting on certain stories as a benefit to our readers. At its best, our comments sections can be a productive platform for readers to engage with our journalism, offer thoughts on coverage and issues, and drive conversation in a respectful, solutions-based way. It's a form of open discourse that can be useful to our community, public officials, journalists and others.
We do not enable comments on everything — exceptions include most crime stories, and coverage involving personal tragedy or sensitive issues that invite personal attacks instead of thoughtful discussion.
You can read more here about our commenting policy and terms of use. More information is also found on our FAQs.
Show less